Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03713632 · ClinicalTrials.gov registry record · Phase 3
Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)
A Phase 3 study of Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 545
- Enrollment target
- 20
- Study locations
NCT03713632 is a Phase 3 study of Hidradenitis Suppurativa that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 545 participants, roughly in line with the 588-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target. The trial reports 20 study locations across 14 states.
The verdict
NCT03713632, a Phase 3 study of Hidradenitis Suppurativa, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 545 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week 52 in subjects with moderate to severe HS. Moreover, this study assessed the safety and tolerability of secukinumab.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Secukinumab
Study Locations (20)
Other
- Novartis Investigative Site - Capital Federal
- Novartis Investigative Site - Ghent
- Novartis Investigative Site - Liège
California
- Novartis Investigative Site - San Diego
- Novartis Investigative Site - Whittier
Florida
- Novartis Investigative Site - Coral Gables
- Novartis Investigative Site - Tampa
Missouri
- Novartis Investigative Site - St Louis
- Novartis Investigative Site - St Louis
Texas
- Novartis Investigative Site - Bellaire
- Novartis Investigative Site - Pflugerville
Georgia
- Novartis Investigative Site - Sandy Springs
Indiana
- Novartis Investigative Site - Indianapolis
Massachusetts
- Novartis Investigative Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 545 participants |
| Start Date | 2019-02-25 |
| Est. Completion | 2022-07-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03713632
The ClinicalTrials.gov registry entry for NCT03713632 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 545 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 588-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03713632 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT03713632 about?
NCT03713632 is a clinical study titled "Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)". The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week 52 in subjects with moderate to severe HS. Moreover, this study assessed...
What is the current status of trial NCT03713632?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 545 participants. The study started on 2019-02-25. Estimated completion is 2022-07-19.
What conditions does trial NCT03713632 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT03713632?
The interventions under investigation include: Placebo (DRUG), Secukinumab (DRUG).
Who is sponsoring clinical trial NCT03713632?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03713632 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
RECRUITING · Phase 3
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
RECRUITING · Phase 3
-
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.